Arcturus Therapeutics (ARCT) Projected to Post Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) will likely be releasing its earnings data after the market closes on Thursday, March 6th. Analysts expect Arcturus Therapeutics to post earnings of ($0.33) per share and revenue of $44.64 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Arcturus Therapeutics Trading Up 3.2 %

ARCT opened at $16.58 on Thursday. Arcturus Therapeutics has a 1-year low of $14.30 and a 1-year high of $45.00. The company has a market capitalization of $449.13 million, a PE ratio of -7.47 and a beta of 2.62. The firm’s 50 day simple moving average is $16.98 and its two-hundred day simple moving average is $18.80.

Analyst Ratings Changes

ARCT has been the subject of a number of analyst reports. BTIG Research started coverage on shares of Arcturus Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $41.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Finally, HC Wainwright restated a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a report on Friday, February 14th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Buy” and a consensus price target of $65.00.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.